Combining two immunotherapy drugs is a more effective treatment for certain metastatic colorectal cancers than using either treatment drug alone.
CheckMate 8HW trial used together, Opdivo (nivolumab) plus Yervoy (ipilimumab) slowed cancer growth in MSI-High metastatic colorectal cancers, a type of colorectal cancer often found in Lynch syndrome.
The FDA approved this combined treatment for MSI-High metastatic colorectal cancer after progression with chemotherapy.
Note: People with Lynch syndrome who have colorectal cancer commonly have MSI-H or dMMR cancers.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02848-4/abstract
Lynch Syndrome Ireland 